Similar to our findings (Fig. 7), the expression levels of ABCB7 and MAP3K7 were significantly lower in SF3B1MUT-MDS patients than in SF3B1WT-MDS patients, which was also confirmed for the cohort excluding CMML (Chronic myelomonocytic leukemia) and RAEB (Refractory anemia with excess blasts) (see Supplementary Fig. S28 online). Here, MAP3K7 is linked to myelodysplastic syndrome with excess blasts.